Kim Tae Hyun, Wu Hong-Gyun, Ahn Soon-Hyun, Jeong Woo-Jin, Cha Wonjae, Eom Keun-Yong
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Department of Human Systems Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Radiat Oncol J. 2024 Sep;42(3):192-199. doi: 10.3857/roj.2024.00164. Epub 2024 Sep 25.
For tonsillar cancer with multiple ipsilateral neck lymph nodes, the safety and efficacy of unilateral radiotherapy (RT) have long been a topic of debate. We performed retrospective analyses of patients having ipsilateral neck lymph nodes treated with unilateral RT in two tertiary referral hospitals.
This study accrued 29 patients who were diagnosed as well-lateralized tonsillar cancer with multiple ipsilateral neck lymph nodes and underwent unilateral RT from March 2000 to March 2020. Patients underwent treatment with one of the following options or a combination of them: induction chemotherapy, surgery, RT, and concurrent chemoradiotherapy. We analyzed the recurrence pattern and survival with special attention to contralateral neck failure. Also, treatment-related toxicities were compared with a 1:1 matched cohort of those who received bilateral RT, using propensity score matching analysis.
At a median follow-up of 68 months, no contralateral neck failure was observed. Five-year actuarial locoregional recurrence-free survival, distant metastasis-free survival, and overall survival were 85.6%, 91.8%, and 92.7%, respectively. Both the acute and chronic grade 2 xerostomia occurred in 10.3% of the patients. When the toxicity for unilateral RT was compared to that of bilateral RT using a propensity score-matched cohort, a significantly lower rate of acute xerostomia was observed in unilateral RT group (55.1% vs. 82.7%, p=0.002), primarily at grade 2 level (10.3% vs. 51.7%, respectively).
The results of our study suggest that unilateral RT can be safely performed in well-lateralized tonsillar cancer patients with multiple ipsilateral neck lymph nodes.
对于伴有多个同侧颈部淋巴结转移的扁桃体癌,单侧放疗(RT)的安全性和有效性长期以来一直是一个争论的话题。我们对两家三级转诊医院中接受单侧放疗治疗同侧颈部淋巴结的患者进行了回顾性分析。
本研究纳入了29例在2000年3月至2020年3月期间被诊断为单侧扁桃体癌且伴有多个同侧颈部淋巴结转移并接受单侧放疗的患者。患者接受以下一种治疗方案或联合治疗:诱导化疗、手术、放疗和同步放化疗。我们分析了复发模式和生存率,特别关注对侧颈部复发情况。此外,使用倾向评分匹配分析,将治疗相关毒性与接受双侧放疗的1:1匹配队列进行比较。
中位随访68个月时,未观察到对侧颈部复发。5年精算局部区域无复发生存率、无远处转移生存率和总生存率分别为85.6%、91.8%和92.7%。10.3%的患者出现了急性和慢性2级口干。当使用倾向评分匹配队列将单侧放疗的毒性与双侧放疗的毒性进行比较时,单侧放疗组急性口干发生率显著较低(55.1%对82.7%,p = 0.002),主要为2级水平(分别为10.3%对51.7%)。
我们的研究结果表明,对于伴有多个同侧颈部淋巴结转移的单侧扁桃体癌患者,可以安全地进行单侧放疗。